Exuma Biotechnology Acquires CAR-T Assets in China

Shanghai – December 14, 2018 – Cooley advised F1 Oncology affiliate Exuma Biotechnology on its acquisition of rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in China. Partner James Lu led the Cooley team advising Exuma Biotechnology.

Exuma Biotechnology will develop and commercialize cellular therapies in Greater China to treat solid tumor malignancies. It will also expand its CAR-T cell processing capabilities at a new facility in Shanghai and its viral manufacturing capabilities at a newly constructed facility in Shenzhen.

"The treatment of cancer is advancing at unprecedented speed, and we are pleased to be playing a role in this rapid and positive evolution," said Gregory Frost, chairman and CEO of F1 Oncology, in a statement.

Exuma Biotechnology is a clinical-stage biotechnology company formed in 2016 to maximize the development and commercialization of enabling products and technology from F1 Oncology in the Greater China markets.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Related Contacts
James Lu Partner, Shanghai
Jane Adams Partner, San Diego
Charity Williams Associate, San Diego
Andrew Harline Associate, Shanghai
Michael Shen Associate, Shanghai
Pan Chen Legal Consultant, Shanghai
Related Practices & Industries

Life Sciences Greater China Biotechnology